How do you pay?

How to pay the least

Ask for the cash price

Truqap

We didn’t find one.

  1. Ask your pharmacy for Truqap’s cash price, and one or two other pharmacies too.
  2. Truqap’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify AZ&Me Prescription Savings Program. For AZ&Me’s Specialty and Primary products, your annual adjusted gross income must be at or below 300% of the Federal Poverty Level Or call 1-800-292-6363.

See if you qualify 

Compare every option

Question
Brand nameTruqap
Authorized genericcapivasertib
Regular genericcapivasertib
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Truqap?
The original
–
–

Brand nameThe maker’s card

TRUQAP Co-Pay Savings Program

Savings card from AstraZeneca

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a month

Sign up on truqap.com 

Or call 1-844-275-2360.

In the maker’s words

“Patients may pay as little as $0 per month for TRUQAP.”

From the maker’s offer on truqap.com, checked October 27, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Truqap itself, from the same company, sold without the brand name, and usually for less. For now Truqap is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

TRUQAP is a kinase inhibitor indicated:

HR-Positive, HER2-Megative Locally Advanced or Metastatic Breast Cancer

  • in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-authorized test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.

PTEN-Deficient Metastatic Androgen Pathway Modulation-Naïve or -Sensitive (mAPMN/S) Prostate Cancer

  • in combination with abiraterone and prednisone for the treatment of adult patients with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer that is PTEN-deficient as detected by an FDA-authorized test.

Source: the FDA label for Truqap (AstraZeneca Pharmaceuticals LP), September 16, 2026. Full label on DailyMed 

Good to know